ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...
Please provide your email address to receive an email when new articles are posted on . Technsophere insulin conferred a similar HbA1c as a rapid-acting analog for children and adolescents with ...
Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumps Subjects utilizing inhaled insulin experienced a ...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products ...
Mannkind Corporation expects to submit a request for a supplemental new drug application meeting to the US Food and Drug Administration for its inhaled human insulin (Afrezza Inhalation Powder).
MannKind Corp., a biopharmaceutical company based in Danbury, on Saturday announced positive results from a study that showed inhaling insulin is as effective as injecting it for treating adults with ...